BSE filing, NSE: GENNEX. Summary written from the filing by ALFA Finder's alert engine.
Gennex Laboratories Ltd: key numbers
- Share price
- ₹9.10
- Market cap
- ₹221.1 Cr
- Revenue (annual)
- ₹172.7 Cr
- Net profit (annual)
- ₹20.98 Cr
- P/E (TTM)
- 9.3×Sector 46.1×
- Promoter holding
- 23.63%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gennex Laboratories Ltd
All →Gennex Laboratories Other Announcement
Gennex Laboratories Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Gennex Laboratories Management Change
Gennex Laboratories announced the appointment of Mr. Dipankar Dasgupta as Independent Director, replacing Mr. Amudala Sreeramulu Nageswar Rao, effective October 1, 2026.
Gennex Laboratories Annual General Meeting
Gennex Laboratories Limited held its 41st electronic Annual General Meeting on September 30, 2026. Proceedings included the adoption of financial statements and appointment of company directors.
Gennex Laboratories Business Update
Subsidiary Deccan Remedies Ltd received approvals from the Drug Control Administration, Andhra Pradesh, to manufacture ten additional pharmaceutical products and test licences at its facility.
Gennex Laboratories Annual General Meeting
Gennex Laboratories Limited announced the closure of its register of members from September 23 to September 30, 2026. This is for the upcoming 41st Annual General Meeting.
Gennex Laboratories Board Meeting Outcome
Gennex Laboratories announced the outcome of its board meeting, approving the draft directors' report and scheduling the 41st Annual General Meeting for September 30, 2026.
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.